Document is current
Any future updates will be listed below
-
Authors
Goodman, Rachel
Johnson, Douglas B. https://orcid.org/0000-0002-6390-773X
- License Information
-
More Information
Article History
Accepted: 29 August 2022
First Online: 20 September 2022
Declarations
:
: DBJ has served on advisory boards or as a consultant for the BMS, Catalyst Biopharma, Iovance, Jansen, Mallinckrodt, Merck, Mosaic ImmunoEngineering, Novartis, Oncosec, Pfizer, Targovax, and Teiko, has received research funding from the BMS and Incyte, and has patents pending for use of MHC-II as a biomarker for immune checkpoint inhibitor response, and abatacept as treatment for immune-related adverse events.
